← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Nail Psoriasis

Phase < 1
Recruiting
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 24
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the effectiveness and safety of deucravactinib in treating nail psoriasis in 20 adult patients. Patients will take deucravacitinib daily for

Who is the study for?
Adults over 18 with chronic plaque psoriasis and nail psoriasis, who are in good health aside from their skin condition. Participants must not have used systemic therapies for psoriasis or biologics within specific time frames before the study starts and be willing to have photos taken of their nails.
What is being tested?
The trial is testing Deucravacitinib, an oral medication, given at a dose of 6 mg daily to treat nail psoriasis. The study will follow twenty patients for 48 weeks, using assessments like the modified Nail Psoriasis Severity Index and photographs to track changes.
What are the potential side effects?
While specific side effects aren't listed here, participants will be monitored for any adverse reactions due to taking Deucravacitinib throughout the nearly one-year-long study period.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the modified Nail Psoriasis Severity Index (mNAPSI) compared to baseline

Side effects data

From 2023 Phase 2 trial • 67 Patients • NCT04877990
25%
COVID-19
13%
Pneumonia
13%
Nasopharyngitis
8%
Upper respiratory tract infection
8%
Cough
8%
Pyrexia
8%
Mouth ulceration
4%
Urinary tract infection
4%
Small intestinal obstruction
4%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
CROHN'S DISEASE
ULCERATIVE COLITIS

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Deucravacitinib 6 mg DailyExperimental Treatment1 Intervention
All participants will receive 6 mg of deucravacitinib daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,646 Previous Clinical Trials
2,342,364 Total Patients Enrolled
7 Trials studying Psoriasis
40,662 Patients Enrolled for Psoriasis
~11 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top